J.B Chemicals & Pharma announces DJSI score of 77

Published On 2025-03-09 05:00 GMT | Update On 2025-03-09 05:00 GMT

Mumbai: J.B. Chemicals & Pharmaceuticals Limited has announced that latest ESG score has been announced by Dow Jones Sustainability Index (DJSI), one of the world’s premier indexes in terms of sustainability.

J. B. Chemicals & Pharmaceuticals Limited’s DJSI score is 77, which will rank presently among the leading pharmaceutical companies in India and also rank among the leaders in Pharma Globally (Sector: DRG Pharmaceuticals, DJSI, S&P Global).

"This achievement underscores the Company’s steadfast commitment to sustainability, corporate responsibility, and environmental, social, and governance (ESG) excellence," JB Chemicals stated.

The DJSI ranking is a premier globally recognized benchmark for corporate sustainability, assessing companies with rigorous evaluation covering Environmental, Social and Governance and industry specific questionnaires, assessing an average of 23 sustainability topic through 150 questions/indicators, evaluating around 13,000 companies worldwide every year.

"JB Pharma’s score reflects its continuous efforts to integrate sustainable practices into its core business operations. Over the past year, JB Pharma has implemented several impactful sustainability initiatives, including renewable energy adoption, rainwater harvesting project, waste reduction programs, increased governance, community development projects etc. These efforts have not only contributed to a positive environmental and social footprint but have also strengthened the Company’s position as a leader in sustainable growth," it added.

"As JB Pharma continues its journey towards a more sustainable future, it remains committed to upholding the highest standards of corporate governance and responsible business practices, ensuring long-term value creation for all stakeholders," it further added.

J.B. Pharma was established in 1976. Besides its strong India presence, which accounts for majority of its revenue, its other two home markets are Russia and South Africa. In India, the company has six brands among the top 300 IPM brands in the country. The company exports its finished formulations to over 40 countries including the USA. Besides supplying branded generic formulations to several countries, it is also manufactures medicated lozenges. It has eightstate of the art manufacturing facilities in India including a dedicated manufacturing facility for lozenges. The manufacturing facilities are certified by leading regulators across the world.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

J.B Chemicals & Pharma announces DJSI score of 77

Similar News

Roche gets negative EMA Committee opinion on Elevidys CMA for 3-7 year olds with Duchenne muscular dystrophy

Expert Committee Clears Ravenbhel to Begin Resmetirom Phase 3 Trial, Asks for BE Data First

Menopause relief drug: USFDA extends review period for Bayer Elinzanetant

Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimer's disease

Troikaa's Fast-Acting Paracetamol Shot Hits Regulatory Hurdle, CDSCO Panel Seeks More Data

Sanofi Sarclisa approved in EU for transplant-eligible newly diagnosed multiple myeloma

Pharma Firm Ignored Safety Gaps Before Deadly Blast, Paid Rs 32 Cr To Victims, Parliament Informed

GSK Blenrep combos approved in EU for treatment of relapsed/refractory multiple myeloma